Alexandra Hochreiter

Durvalumab Prolongs Overall Survival, Whereas Radiation Dose Escalation > 66 Gy Might Improve Long-Term Local Control in Unresectable NSCLC Stage III: Updated Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR)

Zehentmayr, F. (First author), Ruznic, E. (Co-author), Feurstein, P. (Co-author), Langer, B. (Co-author), Grambozov, B. (Co-author), Klebermass, M. (Co-author), Hochreiter, A. (Co-author), Purevdorj, A. (Co-author), Gruber, G. (Co-author), Minasch, D. (Co-author), Böhmer-Breitfelder, B. (Co-author), Steffal, C. (Co-author), Kirchhammer, K. (Co-author), Stranzl, H. (Co-author), Röder, F. (Co-author), Dieckmann, K. (Last author) & ALLSTAR Group, 25 Apr 2025, In: Cancers.

Research output: Contribution to journal › Original Article › peer-review